Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00114387 · ClinicalTrials.gov registry record · Phase 2
VEAPS: Vitamin E Atherosclerosis Prevention Study
A Phase 2 study of Atherosclerosis, sponsored by National Institute on Aging (NIA).
- Completed
- Registry status
- Phase 2
- Development phase
- 353
- Enrollment target
- 1
- Study location
NCT00114387: Completed Phase 2 study of Atherosclerosis, sponsored by National Institute on Aging (NIA).
NCT00114387 is a Phase 2 study of Atherosclerosis that has completed, run by National Institute on Aging (NIA). The registered enrollment target is 353 participants, below the 1,061-participant average among 69 other Atherosclerosis trials with a reported enrollment target (67% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00114387, a Phase 2 study of Atherosclerosis, has completed, sponsored by National Institute on Aging (NIA).
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 353 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of this study is to examine whether vitamin E (DL-alpha-tocopherol) supplementation will reduce the progression of early atherosclerosis in healthy individuals over 40 years of age with low-density lipoprotein (LDL) cholesterol levels greater than or equal to 130mg/dL.
Conditions Studied
Interventions
- DRUG DL-alpha-tocopherol
Study Locations (1)
California
- Atherosclerosis Research Unit, Division of Cardiovascular Medicine, Department of Medicine - Los Angeles
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 353 participants |
| Start Date | 1996-07 |
| Est. Completion | 2000-09 |
| Phase | Phase 2 |
What the finished NCT00114387 record still lists
NCT00114387 is an interventional study that assigns participants to a tested intervention. The registered 353 participants enrollment target is mid-sized for trials with a published cap, below the 1,061-participant average among 69 other Atherosclerosis trials with a reported enrollment target (67% lower).
The record links to 1 condition, with Atherosclerosis appearing as the primary indexed condition, and to 1 intervention - of which DL-alpha-tocopherol is the first listed.
NCT00114387 reports a single indexed study location in California.
Frequently Asked Questions
What is clinical trial NCT00114387 about?
NCT00114387 is a clinical study titled "VEAPS: Vitamin E Atherosclerosis Prevention Study". The purpose of this study is to examine whether vitamin E (DL-alpha-tocopherol) supplementation will reduce the progression of early atherosclerosis in healthy individuals over 40 years of age with low-density lipoprotein (LDL) cholesterol levels greater than or equal to 130mg/dL.
What is the current status of trial NCT00114387?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 353 participants. The study started on 1996-07. Estimated completion is 2000-09.
What conditions does trial NCT00114387 study?
This clinical trial studies the following conditions: Atherosclerosis.
What interventions are being tested in trial NCT00114387?
The interventions under investigation include: DL-alpha-tocopherol (DRUG).
Who is sponsoring clinical trial NCT00114387?
This trial is sponsored by National Institute on Aging (NIA), which has 131 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00114387 being conducted?
This trial has 1 study location across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Atherosclerosis
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT00114387's enrollment target sits among peer trials
353 24th of 69 higher than 46 of 69 other Atherosclerosis trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Atherosclerosis trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Emergency Medicine Cardiovascular Risk Assessment for Lipid Disorders Trial
RECRUITING · Phase 2
-
Cholesterol and Inflammation Lowering Via Bempedoic Acid, an ACL-inhibiting Regimen in HIV Trial (CLEAR HIV Trial)
RECRUITING · Phase 2
-
Advancing Postmenopausal Preventive Therapy
ACTIVE NOT RECRUITING · Phase 2
-
Effects of Angiotensin-Converting Enzyme Inhibitor (Ramipril) Therapy on Blood Vessel Inflammation
COMPLETED · Phase 2
-
Effects of Hormone Therapy on the Immune Systems of Postmenopausal Women With Chronic Infections
COMPLETED · Phase 2
-
An Imaging Study in Patients With Atherosclerosis Taking Rilapladib or Placebo for 12 Weeks
COMPLETED · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT05548296 · 353 participants · Phase 2
A Phase 2 Study of ACR-368 in Endometrial Adenocarcinoma
- NCT05884775 · 353 participants · NA
Novel Digital Patient-Reported Outcomes Tool for Diabetes Management
- NCT02579967 · 354 participants · Phase 2
Pilot Trial of Allogeneic Blood or Marrow Transplantation for Primary Immunodeficiencies
- NCT02610413 · 354 participants
Whole Exome Sequencing in Finding Causative Variants in Germline DNA Samples From Patients With Hypertension Receiving Bevacizumab for Breast Cancer
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia